Effect of TSH on oocyte maturation of PCOS patients with normal thyroid function in IVF

Shaoyuan Xu1,2†, Ying Zhang1,2*, Cancan Qiang3† and Changjun Zhang1,2

Abstract

Background: The serum TSH level of PCOS patients was higher than that of the general female population. For patients with thyroid dysfunction, the abnormal TSH level is negatively related to the outcomes of assisted reproductive technology, but for PCOS patients with normal thyroid function, the effect of TSH level on outcomes of in vitro fertilization has not been reported. In this study, PCOS patients with normal thyroid function were included in this study to evaluate the effect of TSH on the outcomes of IVF-ET.

Methods: A retrospective cohort study was conducted to analyze the clinical data of 3190 patients who underwent IVF-ET in the Department of Human Reproductive Center of Renmin Hospital Hubei University of Medicine from January 2017 to July 2021, including 594 PCOS patients and 2595 non PCOS patients. The IVF-ET outcomes between the two groups were compared; Multi-factor linear regression analysis was used to analyze the correlation between the related variables and the oocyte maturation of PCOS patients; The ROC curve of the effect of TSH on oocyte maturation in PCOS patients was drawn. The PCOS patients were divided into TSH < 2.98 group (n = 454) and TSH ≥ 2.98 group (n = 141) according to ROC threshold TSH 2.98, and the outcomes were compared.

Results: TSH level in PCOS group was significantly higher than that in non-PCOS group (2.42 ± 0.86 vs 2.00 ± 0.89 UU / ml, P < 0.01), and the oocyte maturation rate and 2PN fertilization rate in PCOS group were lower than those in non-PCOS group (90.9% vs 92.4%, P = 0.02) (84.57% vs 86.77%, P = 0.02). There was no significant difference in cleavage rate and high-quality embryo rate between the two groups (P > 0.05); There was no difference in clinical pregnancy rate, abortion rate, ectopic pregnancy rate and live birth rate between the two groups (P > 0.05).

Multi-factor linear regression analysis showed that TSH was negatively correlated with oocyte maturation in PCOS patients (β = -0.124, P = 0.013, 95%CI (-0.027 ~ -0.003)); The oocyte maturation rate in TSH < 2.98 group was significantly higher than that in TSH ≥ 2.98 group (91.7% vs 88.2%, P = 0.001).

Conclusion: The TSH level of PCOS patients with normal thyroid function is higher than that of normal people, and it is negatively correlated with the oocyte maturation in in-vitro fertilization. The ROC curve showed that when TSH > 2.98uIU/ml, the possibility of immature oocytes was higher (specificity 28.9%, sensitivity 83.0%).

Keywords: Fertilization, In vitro, PCOS, TSH, Oocyte maturation, Pregnancy

Introduction

Polycystic ovary syndrome (PCOS) is a kind of endocrine and metabolic disorder disease, which is common in women of childbearing age, with a incidence rate of 15%, and it's main clinical manifestations are rare ovulation or anovulation, accompanied by abnormal glucose and lipid metabolism and hyperandrogenemia [1, 2]. The...
pathogenesis of PCOS is complex, at present it is mainly believed that the pathogenesis of PCOS is related to environmental, genetic, immune and endocrine regulation [3]. In vitro fertilization embryo transfer (IVF-ET) is an effective method to treat infertility in PCOS patients [4].

The hypothalamus pituitary ovary axis and hypothalamus pituitary thyroid axis interact and influence each other. Abnormal thyroid stimulating hormone (TSH) level can affect female metabolism and reproductive system function [5–7]. At the same time, the gonadal axis imbalance caused by endocrine hormone disorders in PCOS patients also affects the pituitary thyroid axis, the serum TSH level of PCOS patients was higher than that of the general female population [8–10]. Thyroid stimulating hormone (TSH) is the most sensitive and commonly used index to evaluate thyroid function [11, 12]. Both The American Society for reproductive medicine (ASRM) and The American Thyroid Association (ATA) recommended routine thyroid function test for pregnant women [13, 14]. For patients with thyroid dysfunction, it is widely acknowledged that abnormal TSH level is related to the decrease of clinical pregnancy rate and increase of abortion rate in assisted reproductive technology [15–17], but for PCOS patients with normal thyroid function, the effect of TSH level on outcomes of IVF-ET has not been rarely reported.

In this study, PCOS patients with normal thyroid function were included in this study to evaluate the effect of TSH on the outcomes of IVF-ET.

Materials and methods
Participants
A retrospective cohort study was conducted to analyze the clinical data of 3190 patients who underwent IVF-ET in the Department of Human Reproductive Center of Renmin Hospital Hubei University of Medicine from January 2017 to July 2021.

Inclusion criteria
① Age < 40; ② AMH > 1 ng/ml; ③ The TSH level measured on the third day of menstruation was in the normal range of our laboratory (0.56–5.91uIU/ml).

Exclusion criteria
① Previous history of thyroid disease; ② High risk factors of recurrent abortion; ③ Patients with underlying diseases who are not suitable for pregnancy.

Three thousand one hundred ninety patients were divided into two groups, including 594 patients in PCOS group and 2595 patients in non PCOS group. According to the threshold TSH2.98 of ROC curve, all the PCOS patients were divided into two groups: TSH < 2.98 group (n = 454) and TSH ≥ 2.98 group (n = 141). Rotterdam criteria [1] were used for the diagnosis of PCOS.

This study was approved by the Ethics Committee of Renmin Hospital, Hubei University of Medicine and conducted in conformity with the Helsinki Declaration.

Ovulation induction protocol
All patients were treated with GnRH-agonist long protocol. Triptorelin 3.75 mg (Germany Huiling Pharmaceutical Co., Ltd.) was injected on the third day of menstruation. After 30 days, gonadotropins (r-FSH, Gonafen, Merck Serono, or HMG, Livzon Medicine) were used for ovulation induction. When multiple follicles matured (the diameter of follicles measured by ultrasound was over 18 mm), 250 μg of recombinant human chorionic gonadotropin (r-HCG, Merck serono) was injected, 36 h later B-ultrasound guided transvaginal aspiration was performed to evaluate the quality of oocytes retrieved. According to the maturation, the oocytes retrieved were divided into three stages: germinal vesicle phase (GV), meiosis metaphase I (M I), meiosis metaphase II (M II), and M II was mature oocytes.

Embryo culture, corpus luteum support and diagnosis of clinical pregnancy
The oocytes retrieved were subjected to embryo culture after conventional IVF fertilization or ICSI fertilization. 16–18 h after fertilization, the pronucleus were observed, and the appearance of two pronucleus was judged as normal fertilization. The embryo scoring method referred to Ziebe etc. [18]. Grade I~II are high-quality embryos; Grade I~III is usable embryo; Grade IV embryos are discarded embryos. High quality embryo rate = (Grade I + Grade II) embryos/total number of embryos, and available embryo rate = (Grade I + Grade II + Grade III)/total number of embryos. From the day of oocytes retrieving, 90 mg/d of vaginal progesterone vaginal sustained-release gel (Merck Serono, Switzerland) and 20 mg/d of oral dydrogesterone (Solvay Pharma, Netherlands) were used for luteal support. 14 days after embryo transfer, the positive serum HCG was judged as biochemical pregnancy, 30 days after embryo transfer, the original fetal heart beat was detected by B-ultrasound, which was judged as clinical pregnancy, the luteal support medication was continued until 60 days after embryo transfer. Pregnancy loss occurring before 12 weeks of gestation is judged as early spontaneous abortion.
Observation indicators
ART cycle characteristics and embryologic outcomes: Oocyte maturation rate (number of metaphase II (MII) stage oocytes/number of oocytes retrieved × 100%), 2PN fertilization rate (2 pronuclei number/number of oocytes retrieved × 100%), High quality embryo rate (number of high-quality embryos/normal cleavage number × 100%).

Pregnancy outcomes: clinical pregnancy rate (number of pregnancy cycles/number of transplantation cycles × 100%), early spontaneous abortion rate (number of abortion cycles before 12 weeks/number of pregnancy cycles × 100%), live birth rate (number of births of live babies/number of total transplantation cycles × 100%).

Statistical method
SPSS22.0 software was used for statistical analysis. The measurement data conform to the normal distribution expressed by the mean standard deviation (Mean±SD), and the comparison between groups was made by one-way ANOVA. The counting data is expressed by the rate (%), and the comparison between groups adopts χ2 test; multi-factor linear regression analysis was used to exclude the influence of confounding factor and analyze the related variables affecting the oocyte maturation of PCOS patients. The ROC curve of the effect of TSH on oocyte maturation of PCOS patients was drawn. P<0.05 was statistically significant.

Result
Comparison of Baseline characteristics of PCOS group and non-PCOS group (see Table 1 for details)
There were significant differences in AMH, AFC, body weight, BMI, basal endocrine LH, T, PRL between the PCOS group and non-PCOS group (P < 0.001). TSH in PCOS group was significantly higher than that in non-PCOS group (2.42 ± 0.86 vs 2.00 ± 0.89 uIU/ml, P < 0.001).

Comparison of embryologic outcomes and pregnancy outcomes of PCOS group and non-PCOS group (see Table 2 for details)
Compared with non-PCOS group, Gn used Dosage, Number of oocytes retrieved, Number of MII stage oocytes, Number of available embryos and Number of high-quality embryos in PCOS group were significantly higher than those in non-PCOS group. The oocyte maturation rate and 2PN fertilization rate in PCOS group were lower than those in non-PCOS group (90.9% vs 92.4%, P = 0.02) (84.57% vs 86.77%, P = 0.02), and there was no significant difference in cleavage rate and high-quality embryo rate between the two groups (P>0.05); There was no difference in clinical pregnancy rate, early abortion rate, ectopic pregnancy rate and live birth rate between the two groups (P>0.05).

Table 1 Characteristic of PCOS group and non-PCOS group

| Characteristic                  | PCOS Group (n = 595) | Non-PCOS Group (n = 2595) | t/χ2 value | P value |
|--------------------------------|----------------------|---------------------------|------------|---------|
| TSH (uIU/ml)                   | 2.42 ± 0.86          | 2.00 ± 0.89               | 107.79     | <0.001***|
| Age (year)                     | 30.58 ± 3.03         | 30.81 ± 3.35              | 2.35       | 0.125   |
| Infertility duration (year)    | 3.41 ± 2.24          | 3.42 ± 2.46               | 0.006      | 0.937   |
| AMH (ng/ml)                    | 10.58 ± 3.972        | 4.32 ± 1.794              | 3144.14    | <0.001***|
| Basal serum FSH (IU/L)         | 6.27 ± 1.48          | 6.20 ± 1.88               | 0.74       | 0.388   |
| Basal serum LH (IU/L)          | 9.77 ± 10.68         | 6.88 ± 5.66               | 81.15      | <0.001***|
| Basal serum E2 (pg/ml)         | 44.26 ± 19.17        | 45.53 ± 20.91             | 1.58       | 0.209   |
| Basal serum P (ng/ml)          | 0.58 ± 0.38          | 0.59 ± 0.39               | 0.22       | 0.639   |
| Basal serum T (ng/ml)          | 0.60 ± 0.25          | 0.51 ± 0.22               | 76.78      | <0.001***|
| Basal serum PRL (ng/ml)        | 11.91 ± 6.08         | 13.24 ± 6.39              | 20.80      | <0.001***|
| Antral Follicle Counting(AFC)) | 12.18 ± 3.98         | 7.69 ± 2.54               | 1078.91    | <0.001***|
| Height (cm)                    | 159.01 ± 5.42        | 158.89 ± 5.34             | 0.25       | 0.616   |
| Weight (kg)                    | 61.44 ± 10.15        | 58.56 ± 10.11             | 39.24      | <0.001***|
| Body Mass Index (kg/m2)        | 24.30 ± 3.93         | 23.18 ± 3.77              | 41.64      | <0.001***|

* P<0.05  
** P<0.01  
*** P<0.001 for t test
Table 2  Embryologic outcomes and pregnancy outcomes of PCOS group and non-PCOS group

| Outcomes                              | PCOS Group (n = 595) | Non-PCOS Group (n = 2595) | t/χ² value | P value  |
|---------------------------------------|----------------------|---------------------------|------------|----------|
| Gn used dosage (IU)                   | 2268.67 ± 889.98     | 2564.74 ± 979.87          | 45.67      | < 0.001*** |
| Gn used duration (d)                  | 11.57 ± 1.90          | 11.40 ± 2.46              | 2.46       | 0.116    |
| FSH levels on HCG trigger day (IU/L)  | 13.46 ± 4.73          | 17.28 ± 6.19              | 193.59     | < 0.001*** |
| LH levels on HCG trigger day (IU/L)   | 1.06 ± 0.83           | 1.35 ± 1.09               | 35.59      | < 0.001*** |
| E2 levels on HCG trigger day (pg/ml)  | 2737.28 ± 1193.36     | 2625.42 ± 1152.41         | 4.39       | 0.036*   |
| P levels on HCG trigger day (ng/ml)   | 0.75 ± 0.42           | 0.80 ± 0.38               | 8.74       | 0.003**  |
| Endometrial thickness on HCG trigger day (mm) | 11.71 ± 2.54         | 11.64 ± 2.59             | 0.31       | 0.573    |
| Number of oocytes retrieved           | 11.08 ± 2.84          | 9.60 ± 2.61               | 150.26     | < 0.001*** |
| Number of MII stage oocytes           | 10.05 ± 2.76          | 8.89 ± 2.64               | 90.68      | < 0.001*** |
| Oocyte maturation rate (%)            | 90.7% (5980/6594)     | 92.6% (23,082/24917)       | 25.57      | < 0.001*** |
| 2PN fertilization rate (%)            | 84.57%                | 86.77%                    | 13.35      | < 0.001*** |
| Cleavage rate (%)                    | 99.38%                | 99.30%                    | 0.29       | 0.588    |
| Number of useable embryos            | 4.20 ± 1.319          | 3.91 ± 1.233              | 26.90      | < 0.001*** |
| Number of high-quality embryos       | 3.16 ± 1.66           | 2.95 ± 1.58               | 8.83       | 0.003**  |
| High-quality embryo rate (%)         | 70.6%                 | 71.0%                     | 0.13       | 0.716    |
| Clinical pregnancy rate (%)          | 62.7% (373/595)       | 62.7% (1628/2595)         | 0          | 0.983    |
| Ectopic pregnancy rate (%)           | 0.8% (3/373)          | 1.4% (23/1628)            | 0.87       | 0.349    |
| Early abortion rate (%)              | 15.8% (59/373)        | 13.5% (220/1628)          | 1.34       | 0.247    |
| Live birth rate (%)                  | 52.3% (311/595)       | 53.3% (1388/2595)         | 0.28       | 0.591    |

* P < 0.05
** P < 0.01
*** P < 0.001 for t test or Chi-square test

Table 3  Linear regression analysis results of oocyte maturation-related factors

| Variable                              | Regression coefficient B | Standard error | Standard regression coefficient β | t value | P value | 95% confidence interval |
|---------------------------------------|--------------------------|----------------|-----------------------------------|---------|---------|------------------------|
| TSH (uIU/ml)                          | -0.015                   | 0.006          | -0.124                            | -2.487  | 0.013   | -0.027 ~ -0.003        |
| Age (year)                            | 0.002                    | 0.002          | 0.068                             | 1.263   | 0.208   | -0.001 ~ 0.006         |
| Infertility duration (year)           | 0.001                    | 0.002          | 0.015                             | 0.285   | 0.776   | -0.004 ~ 0.006         |
| AMH (ng/ml)                           | 0.002                    | 0.002          | 0.083                             | 1.418   | 0.157   | -0.001 ~ 0.005         |
| Basal serum FSH (IU/L)                | 0.001                    | 0.004          | 0.015                             | 0.281   | 0.779   | -0.007 ~ 0.010         |
| Basal serum LH (IU/L)                 | 0.000                    | 0.000          | 0.043                             | 0.828   | 0.408   | -0.001 ~ 0.001         |
| Basal serum E2 (pg/ml)                | 1.650E-5                 | 0.000          | 0.003                             | 0.56    | 0.575   | -0.001 ~ 0.001         |
| Basal serum P (ng/ml)                 | 0.016                    | 0.015          | 0.055                             | 1.060   | 0.290   | -0.013 ~ 0.044         |
| Basal serum T (ng/ml)                 | -0.001                   | 0.021          | -0.002                            | -0.039  | 0.969   | -0.042 ~ 0.041         |
| Antral Follicle Counting(AFC))        | 0.001                    | 0.002          | 0.029                             | 0.511   | 0.610   | -0.002 ~ 0.004         |
| Body Mass Index (kg/m2)               | 0.002                    | 0.002          | 0.081                             | 1.281   | 0.201   | -0.001 ~ 0.006         |
| Gn used dosage (IU)                   | 1.049E-5                 | 0.000          | 0.087                             | 0.764   | 0.445   | 0.000 ~ 0.000          |
| Gn used duration (d)                  | 0.003                    | 0.005          | 0.048                             | 0.568   | 0.570   | -0.007 ~ 0.013         |
| FSH levels on HCG trigger day (IU/L)  | 2.079E-5                 | 0.002          | 0.001                             | 0.111   | 0.991   | -0.004 ~ 0.004         |
| LH levels on HCG trigger day (IU/L)   | 3.135E-5                 | 0.009          | 0.000                             | 0.003   | 0.997   | -0.018 ~ 0.018         |
| E2 levels on HCG trigger day (pg/ml)  | 4.636E-6                 | 0.000          | 0.048                             | 0.910   | 0.364   | 0.000 ~ 0.000          |
| P levels on HCG trigger day (ng/ml)   | 0.007                    | 0.016          | 0.024                             | 0.419   | 0.676   | -0.025 ~ 0.038         |
| Endometrial thickness on HCG trigger day (mm) | -0.002                 | 0.002          | -0.044                            | -0.874  | 0.383   | -0.006 ~ 0.002         |
Linear regression analysis between related variables and oocyte maturation of each PCOS patient (see Table 3 for details)

The multi-factor linear regression analysis was used to evaluate the correlation between related variables and oocyte maturation of each PCOS patients. After controlled for confounding factors: Age, Infertility duration, AMH, Basal serum FSH, LH, E2, P, T, AFC, BMI, Gn used dosage, Gn used duration, the results showed that TSH was negatively correlated with oocyte maturation of each PCOS patient \[\beta = -0.124, P = 0.013,95\% CI (-0.027 \sim -0.003)\].

ROC curve of effect of TSH on oocyte maturation of each PCOS patient and Comparison of TSH < 2.98 group and TSH \(\geq 2.98\) group (see Table 4 for details)

According to the oocyte maturation of each patient, the ROC curve of TSH predicting oocyte maturation of each PCOS patient was drawn. The results showed that the area under the curve was 0.550, the cut-off value was TSH 2.98 uIU/ml, the specificity was 28.9%, the sensitivity was 83.0%, \(P = 0.037\).

Five hundred ninety-five PCOS patients were divided into two groups according to the threshold of TSH 2.98

| Parameter                                      | TSH < 2.98 group (n = 454) | TSH \(\geq 2.98\) group (n = 141) | t/χ2 value | \(P\) value |
|------------------------------------------------|----------------------------|----------------------------------|------------|-------------|
| TSH (uIU/ml)                                   | 2.06±0.62                  | 3.56±0.41                        | 716.78     | <0.001***   |
| Age (year)                                     | 30.64±3.09                 | 30.41±2.85                       | 0.59       | 0.442       |
| Infertility duration (year)                    | 3.39±2.29                  | 3.47±2.10                        | 0.13       | 0.713       |
| AMH (ng/ml)                                    | 10.58±4.00                 | 10.55±3.89                       | 0.009      | 0.926       |
| Basal serum FSH (IU/L)                         | 6.26±1.46                  | 6.33±1.55                        | 0.25       | 0.613       |
| Basal serum LH (IU/L)                          | 9.80±11.60                 | 9.66±7.02                        | 0.01       | 0.892       |
| Basal serum E2 (pg/ml)                         | 44.57±18.79                | 43.31±20.30                      | 0.42       | 0.514       |
| Basal serum P (ng/ml)                          | 0.58±0.39                  | 0.57±0.36                        | 0.02       | 0.868       |
| Basal serum T (ng/ml)                          | 0.61±0.25                  | 0.59±0.28                        | 0.58       | 0.444       |
| Basal serum PRL (ng/ml)                        | 11.66±6.24                 | 12.69±5.44                       | 3.01       | 0.083       |
| Antral Follicle Counting (AFC)                 | 12.04±3.98                 | 12.65±3.96                       | 2.32       | 0.128       |
| Height (cm)                                    | 159.04±5.41                | 158.89±5.47                      | 0.08       | 0.769       |
| Weight (kg)                                    | 61.39±10.41                | 61.65±9.27                       | 0.06       | 0.792       |
| Body Mass Index (kg/m2)                        | 24.25±3.99                 | 24.45±3.75                       | 0.26       | 0.605       |
| Gn used dosage (IU)                            | 2278.91±911.08             | 2235.69±820.56                   | 0.253      | 0.615       |
| Gn used duration (d)                           | 11.65±1.91                 | 11.31±1.81                       | 3.50       | 0.062       |
| FSH levels on HCG trigger day (IU/L)           | 13.36±4.80                 | 13.80±4.48                       | 0.90       | 0.341       |
| LH levels on HCG trigger day (IU/L)            | 1.06±0.84                  | 1.03±0.82                        | 0.14       | 0.708       |
| E2 levels on HCG trigger day (pg/ml)           | 2747.72±1157.98            | 2703.69±1305.39                  | 0.14       | 0.705       |
| P levels on HCG trigger day (ng/ml)            | 0.75±0.43                  | 0.76±0.38                        | 0.04       | 0.825       |
| Endometrial thickness on HCG trigger day (mm)  | 11.71±2.61                 | 11.71±2.34                       | 0.001      | 0.982       |
| Number of oocytes retrieved                    | 11.02±2.75                 | 11.28±3.10                       | 0.92       | 0.336       |
| Number of MII stage oocytes                    | 10.09±2.72                 | 9.91±2.86                        | 0.49       | 0.483       |
| Oocyte maturation rate (%)                     | 91.7%                      | 88.2%                            | 10.86      | 0.001**     |
| 2PN fertilization rate (%)                     | 84.61%                     | 84.48%                           | 0.01       | 0.914       |
| Cleavage rate (%)                              | 99.51%                     | 98.96%                           | 3.73       | 0.054       |
| Number of useable embryos                      | 4.24±1.31                  | 4.06±1.34                        | 2.02       | 0.156       |
| Number of high-quality embryos                 | 3.21±1.66                  | 3.02±1.69                        | 1.33       | 0.249       |
| High-quality embryo rate (%)                   | 71.1%                      | 69.0%                            | 0.63       | 0.426       |
| Clinical pregnancy rate (%)                    | 64.3% (292/454)            | 57.4% (81/141)                   | 2.17       | 0.085       |
| Ectopic pregnancy rate (%)                     | 1.0% (3/292)               | 0% (0/81)                        | 0.83       | 0.479       |
| Early abortion rate (%)                        | 15.4% (45/292)             | 17.3% (14/81)                    | 0.16       | 0.398       |
| Live birth rate (%)                            | 53.7% (244/454)            | 47.5% (67/141)                   | 1.67       | 0.116       |

* \(P < 0.05\)
** \(P < 0.01\)
*** \(P < 0.001\) for t test or Chi-square test
in ROC curve. The results showed that the oocyte maturation of TSH < 2.98 group was significantly lower than that of TSH ≥ 2.98 group (91.7% vs 88.2%, \( P = 0.001 \)) (Fig. 1A); There was no difference in 2PN fertilization rate between the two groups (84.61% vs 84.48%, \( P = 0.914 \)) (Fig. 1B); The clinical pregnancy rate (64.3% vs 57.4%, \( P = 0.085 \)) (Fig. 1C) and live birth rate (53.7% vs 47.5%, \( P = 0.116 \)) (Fig. 1D) in TSH < 2.98 group were lower than those in TSH ≥ 2.98 group, but the difference was not statistically significant.

**Discussion**

Thyroid hormone is an endocrine hormone that can maintain nervous system excitation, promote the development of tissues and organs, and regulate metabolism [12].

Due to the interaction between the hypothalamus pituitary ovary axis and the hypothalamus pituitary thyroid axis, thyroid hormone can have negative feedback effect on hypothalamus and pituitary. When TSH level is abnormal, it will affect hypothalamic function, resulting in abnormal hypothalamus pituitary gonad axis function [5–7]. Some studies have shown that the majority of female patients with thyroid dysfunction have symptoms such as irregular menstrual cycle, rare menstruation, irregular uterine bleeding, and some of them have polycystic ovarian changes with abnormal blood glucose metabolism and lipid metabolism disorder [19–21], which are considered to be related to insulin resistance and islet cell damage. At the same time, the imbalance of gonadal axis in PCOS patients may affect the pituitary thyroid axis. Many studies found that PCOS patients with severe hyperandrogenemia and insulin resistance are prone to be associated with abnormal thyroid function [22, 23]. Compared with normal women of childbearing age, PCOS patients are often accompanied by elevated TSH [8–10]. It is not known whether the elevated TSH levels in PCOS patients with normal thyroid function is associated with negative outcomes of in-vitro fertilization, such as poor oocyte maturation, low fertilization rate and high incidence of OHSS [24–26].

Our study showed that the average TSH level of PCOS patients with normal thyroid function was significantly higher than that of non-PCOS patients (2.42 ± 0.86 VS 2.00 ± 0.89, \( P < 0.001 \)). This is consistent with the results of literature studies reported so far. The oocyte maturation rate of PCOS group was lower than that of non-PCOS group (90.9% vs 92.4%, \( P = 0.02 \)), which further led to the lower 2PN fertilization rate in PCOS group than that in non-PCOS group (84.57% vs 86.77%, \( P = 0.02 \)). However, there was no significant difference in cleavage rate and high-quality embryo rate between the two groups, and the pregnancy outcomes including clinical pregnancy rate, abortion rate and live birth rate were

![Fig. 1 Distribution of Reproductive outcomes of TSH < 2.98 group and TSH ≥ 2.98 group. A Oocyte maturation rate; B 2PN fertilization rate; C Clinical pregnancy rate; D Live birth rate](image-url)
of childbearing age before pregnancy is higher than
lines which suggested that if the TSH level of women
Society for reproductive medicine (ASRM) issued guide-
be controlled before IVF-ET at present. The American
this paper.

was not detected in this study, which is the deficiency of
reflect the state of thyroid function. TSH level after COH
transient, the increased TSH after COH can not really

group. However, the impact of COH on TSH may be
mechanism of the influence of TSH on oocyte quality in
embryo development potential. Those maybe the main
TSH on oocytes, so there was no significant difference
between embryo outcome and pregnancy outcome. We
adopt multi-factor linear regression analysis to eval-
uate the relationship between oocyte maturation and
related variables. The results showed that TSH was nega-
tively correlated with oocyte maturation of each patient
[β = -1.24, P = 0.013, 95% CI (-0.027 ~ -0.003)], which sug-
gested that TSH might be an independent risk factor for
oocyte maturation in PCOS patients with normal thyroid
function when undergoing IVF-ET.

TSH receptors are widely expressed in human oocytes,
cumulus cells and granulosa cells of ovary. TSH cooper-
ates with FSH to regulate the proliferation, apoptosis
and morphological differentiation of granulosa cells, and
play a direct role in promoting the function of granulosa
cells [27]. TSH promotes the production of LH and hCG
receptors on the surface of granular cells, while there
is a close relationship between granulosa cells in folli-
cles and oocytes, and gap junctions exist between them,
the information transmission, mutual promotion and
synchronous development between cells was put in to
effect depend on the connexins [28]. The functional sta-
tus of granulosa cells directly affects the maturation of
oocytes, granulosa cells also support oocyte maturation
in an endocrine manner, and affects fertilization and even
embryo development potential. Those maybe the main
mechanism of the influence of TSH on oocyte quality in
PCOS patients. In addition, the E2 levels on hCG trig-
ner day of PCOS group is greater than that of non-PCOS
 group, and it is reported that the supraphysiological E2
levels during COH will also lead to the transient increase
of TSH, this is mainly due to the increase of thyroxine
binding protein caused by the super physiological high
estrogen level in the serum, which reduces the concen-
tration of free thyroid hormone and then causes the
increase of serum TSH. Studies shown that the concen-
tration of TSH increases with the increase of super physi-
ological E2 level [29]. This may be another mechanism
by which TSH affects oocyte maturation rate in PCOS
group. However, the impact of of COH on TSH may be
transient, the increased TSH after COH can not really
reflect the state of thyroid function. TSH level after COH
was not detected in this study, which is the deficiency of
this paper.

There is no unified standard for what levels TSH should
be controlled before IVF-ET at present. The American
Society for reproductive medicine (ASRM) issued guide-
lines which suggested that if the TSH level of women of
childbearing age before pregnancy is higher than
2.5mIU/ L, it is feasible to monitor the serum TSH level
for many times. Once the serum TSH level is higher
than 4.0mIU/L, levothyroxine can be used to maintain
the serum TSH level below 2.5mIU/ L [14]. But it is con-
troversial whether or not to use 2.5mIU/L. thresholds
for upper limit of TSH in first-trimester pregnancy and
infertility [30–32].

In this study, we plotted the ROC curve of the effect of
TSH on the oocyte maturity of each PCOS patient. The
results showed that the area under the curve was 0.550,
\( p = 0.037 \), and the specificity was 28.9%, the sensi-
tivity was 83.0%. According to the cut-off threshold TSH
2.98uIU/ml, the patients were divided into two groups.
There was a significant difference in oocyte maturity
between the two groups (\( p < 0.001 \)); The clinical preg-
nancy rate (64.3% vs 57.4%, \( p = 0.085 \)) and Live birth
rate (53.7% vs 47.5%, \( p = 0.116 \)) in TSH < 2.98 group was
higher than that of TSH \( \geq 2.98 \) group, but the difference
was not statistically significant. Therefore, our results
suggest that when TSH \( \geq 2.98 \)uIU/ml, the possibility of
oocyte immaturity is higher (specificity 28.9%, sensi-
tivity 83.0%), and it may have a negative effect on preg-
nancy outcomes.

Conclusion
The TSH level of PCOS patients with normal thyroid
function is higher than that of normal people, and it is
negatively related to the oocyte maturation in IVF. We
suggest that for PCOS patients with normal thyroid func-
tion, when TSH is higher than 2.98uIU/ml, intervention
should be given before IVF cycle was conducted, which
may be helpful to improve oocyte maturation.

Acknowledgements
None

Authors' contributions
S.X contributed to statistical analysis and interpretation of data and draft-
ing of the manuscript. Y.Z and C.Q conceived and designed this study,
performed statistical analysis and participated in the discussion. S.X and
C.Q were involved in acquisition, analysis and interpretation of data.
S.X, Y.Z and C.Q participated in the discussion and critically revised the
manuscript. All authors have read and approved the final version of the
manuscript.

Funding
The study was supported by Young Scientists Fund of the National Natural
Science Foundation of China (Grant No.82101726).

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Renmin Hospital, Hubei
University of Medicine and has been performed in accordance with the
principles of Declaration of Helsinki. Each patient has signed an informed
consent on obtaining and analyzing their clinical data prior to the initiation of IVF/ICSI-ET treatment.

**Consent for publication**

Not applicable.

**Competing interests**

None

**Author details**
1 Department of Human Reproductive Center, Renmin Hospital, Hubei University of Medicine, Shiyan, China. 2 Hubei Clinical Research Center for Reproductive Medicine, Shiyan, Hubei, China. 3 Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.

**Received:** 13 June 2022  **Accepted:** 23 August 2022

**Published online:** 02 September 2022

**References**

1. Rushing JS, Santoro N. Fertility issues in polycystic ovarian disease: a systematic approach. Endocrinol Metab Clin North Am. 2021;50(1):43–55.

2. Shah AK, Yadav BK, Suri A, et al. Study on lipoprotein-a and PAI-1 in women with polycystic ovary syndrome. Horm Mol Biol Clin Investig. 2022. https://doi.org/10.1015/hmbci-2021-00444. Online ahead of print.

3. Claudia, Rapeport, Roy et al.: The source of polycystic ovarian syndrome. [J]. Clin Med Insights Reprod Health. 2019;13:2147483647–2147483647.

4. Tang K, Wu L, Luo Y, Gong B. In vitro fertilization outcomes in women with polycystic ovary syndrome: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021;259:146–52.

5. Saran S, Gupta BS, Philip R, et al. Effect of hypothyroidism on female reproductive hormones[J]. Indian J Endocrinol Metab. 2016;20(1):108–13.

6. Sun J, Hui C, Xia T, et al. Effect of hypothyroidism on the hypothalamic–pituitary–ovarian axis and reproductive function of pregnant rats[J]. BMC Endocr Disord. 2018;18(1):30.

7. Li D, Hu S, Meng X, Yu X. Changes in thyroid function during controlled ovarian hyperstimulation (COH) and its impact on assisted reproduction technology (ART) outcomes: a systematic review and meta-analysis. J Assist Reprod Genet. 2021;38(9):2227–35.

8. Lee HJ, Jo HN, Noh HK, Kim SH, Joo JK. Is there association between thyroid stimulating hormone levels and the four phenotypes in polycystic ovary syndrome? GenePol Pol. 2022. https://doi.org/10.5603/GPa2021.0239. Online ahead of print.

9. Glinkborg D, Rubin KH, Nybo M, Andersen M. Increased risk of thyroid disease in Danish women with polycystic ovary syndrome: a cohort study. Endocr Connect. 2019;8(10):1405–15.

10. de-Medeiros SF, Yamamoto MMW, de-Medeiros MAS, Barbosa JS, Nordest. Should subclinical hypothyroidism be an exclusion criterion for polycystic ovary syndrome? J Reprod Infertil. 2017;18(2):242–50.

11. Davis MG, Phillips J. Hypothyroidism: Diagnosis and Evidence-Based Treatment. J Midwifery Women's Health. 2022;67(3):394–97.

12. National Guideline Centre (UK). Thyroid function tests: Thyroid disease: assessment and management: Evidence review. C London: National Institute for Health and Care Excellence (NICE), 2019.

13. Alexander EH, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. [J] Thyroid. 2017;27(3):315–89.

14. Practice Committee of the American Society for Reproductive Medicine: Subclinical hypothyroidism in the infertile female population: a guideline[J]. Fertil Steril. 2015;104(3):S45–S53.

15. Grove-Laugesen D, Aaskov C, Ebbehoj E, Knudsen UB. Preconception thyrotropin level in euthyroid women is inversely associated with the live birth rate in first in vitro fertilization cycle. Acta Obstet Gynecol Scand. 2019;98(7):929–36.

16. Wadhwa L, Marghret KM, Arora S. Evaluation of reproductive outcome in infertile hypothyroid women on thyroxine therapy. J Hum Reprod Sci. 2020;13(4):272–6.

17. Repelaer van Driel-Delpratt CC, van Dam EWC, van de Ven PM, Aissa K, Ter Haar MK, Feenstra V, de Roos A, Beelen G, Schats R, Lambalk CB. Thyroid function and IVF outcome for different indications of subfertility. Reprod Fertil. 2021;20(6):280–291.

18. Ziebe S, Petersen K, Lindenberg S, et al. Embryo morphology or cleavage stage: how to select the best embryos for transfer after in vitro fertilization[J]. Hum Reprod. 1997;12(7):1545–9.

19. Cai J, Zhang Y, Wang Y, Li S, Wang L, Zheng J, Jiang Y, Dong Y, Zhou H, Hu Y, Ma J, Liu W, Tao T. High thyroid stimulating hormone level is associated with hyperandrogenism in eutryroid Polycystic Ovary Syndrome (PCOS) women, independent of age, BMI, and thyroid autoimmunity: a cross-sectional analysis. Front Endocrinol (Lausanne). 2019;10(10):222.

20. Sheikhi V, Heidari Z. Increase in thyrotropin is associated with an increase in serum prolactin in eutryroid subjects and patients with subclinical hypothyroidism. Med J Islam Repub Iran. 2021;15(35):167.

21. S, Mb V. A study of lipid profile in patients with subclinical hypothyroidism. J Assoc Physicians India. 2022;70(4):11–2.

22. Singhi J, Wong H, Ahluwalia N, Go RM, Guerrero-Go MA. Metabolic, hormonal, immunologic, and genetic factors associated with the incidence of thyroid disorders in polycystic ovarian syndrome patients. Cureus. 2020;12(11):e1681.

23. Raj D, Pooja F, Chhabria P, Kalpana F, Lohana S, Lal K, Shahid W, Naz S, Shahid S, Khalid D. Frequency of subclinical hypothyroidism in women with polycystic ovary syndrome. Cureus. 2021;13(9):e17722.

24. Sun B, Ma Y, Li L, Hu L, Wang F, Zhang Y, Dai S, Sun Y. Factors associated with Ovarian Hyperstimulation Syndrome (OHSS) severity in women with polycystic ovary syndrome undergoing IVF/ICSI. Front Endocrinol (Lausanne). 2019;11(11):e15957.

25. Gong X, Li H, Zhao Y. The Improvement and Clinical Application of Human Oocyte In Vitro Maturation (IVM). Reprod Sci. 2022;29(8):2127–35.

26. Xu Y, Qiao J. Comparison of in vitro maturation and in vitro fertilization for polycystic ovarian syndrome patients: a systematic review and meta-analysis. Ann Transl Med. 2021;9(15):1235.

27. Asahara S, Sato A, Aljomad A, et al. Thyroid hormone synergizes with follicle stimulating hormone to inhibit apoptosis in porcine granulosa cells selectively from small follicles[J]. Kobe J Med. 2003;49(5–6):107–16.

28. Mintziori G, Goulis DG. In vitro fertilization/intracytoplasmic insemination and thyroid function: reviewing the evidence. Metabolism. 2018;86:44–8.

29. Noventa M, Riva A, Buzzaccarini G, et al. P–680 Thyroid function in eutryroid women during controlled ovarian stimulation (COH): does the TSH fluctuations have an impact on IVF outcomes? [J]. Human Reproduction. 2021;36(Supplement_1)dead1b30.679.

30. Rao M, Zeng Z, Zhou F, et al. Effect of levothyroxine supplementation on pregnancy loss and preterm birth in women with subclinical hypothyroidism and thyroid autoimmunity: a systematic review and meta-analysis[J]. Hum Reprod Update. 2019;25(3):344–61.

31. Cai YY, Zhong LP, Guan J, et al.Outcome of in vitro fertilization in women with subclinical hypothyroidism[J]. Reprod Biol Endocrinol. 2017;15(1):1–6.

32. Karakis LS, Kiyak H, Okmen B, et al. Impact of preconception serum thyroid stimulating hormone values ranging between 2.5 and 4.5 mIU/L on live birth rates following ovulation induction and intratine insemination treatment for unexplained infertility[J]. BMC Women’s Health. 2021;21(1):1–7.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.